Switzerland-headquartered ADC Therapeutics has announced that it plans to discontinue the Phase II LOTIS-9 clinical trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). 22 July 2023
Privately-held Recludix Pharma has agreed a deal with French pharma major Sanofi to develop and commercialize oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for immunological and inflammatory (I&I) diseases. 21 July 2023
Polish clinical-stage biotech Molecure (WSE: MOC) revealed that it has successfully closed a secondary public offering (SPO) and entered into subscription agreements for all 2,776,000 H shares offered by way of private placement, within the authorized capital. 21 July 2023
Announcing a range of cost-cutting measures, the chief executive of Swiss biotech Idorsia has said it will take “longer than originally planned” for Quviviq (daridorexant) to become a commercial success. 21 July 2023
Boston, USA-based biotech start-up Jnana Therapeutics has appointed Dr George Vratsanos as its chief medical officer and head of research and development. 20 July 2023
A new analysis of clinical research into selinexor suggests it could be an effective maintenance therapy for certain people with endometrial cancer. 19 July 2023
Privately held, venture-funded biotech Revolo Biotherapeutics today announced additional data from its proof of concept, two-week, three-dose, Phase IIa clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE). 18 July 2023
UK-based CAR-T therapies specialist Leucid Bio today announced the appointment of Filippo Petti as its chief executive (CEO), with immediate effect. 18 July 2023
Mirum Pharmaceuticals, a US biopharma dedicated to transforming the treatment of rare liver diseases, is to buy Travere Therapeutics’ bile acid product portfolio. 17 July 2023
Belgo-Dutch autoimmune diseases specialist argenx has announced positive top-line results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in chronic inflammatory demyelinating polyneuropathy (CIDP). 17 July 2023
Elmar Schnee has been named the new executive chairman of EnteroBiotix, a company that claims to be pioneering the future of modern medicine through microbiome-modulating therapeutics. 17 July 2023
On Sunday, Singapore-headquartered TauRx Pharmaceuticals presented new data from the Phase III LUCIDITY trial that measured the impact of the company’s drug candidate, hydromethylthionine mesylate (HMTM), on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration 17 July 2023
After markets closed on Thursday, US clinical-stage biotech Theseus Pharmaceuticals announced that it is discontinuing enrollment in the ongoing Phase I/II study and terminating development of its lead candidate THE-630 in patients with gastrointestinal stromal tumors (GIST). 14 July 2023
US cell and gene therapy biotech Frequency Therapeutics saw its share leap more than 62% to $0.65 pre-market Friday, after announcing an agreement with RNA editing company Korro Bio to merge in an all-stock transaction. 14 July 2023
Shares of First Wave BioPharma closed down more than 32% at $0.90 on Thursday, after the company said a Phase II study of an enhanced formulation of its adrulipase drug candidate seems likely to have missed its primary efficacy endpoint. 14 July 2023
Privately-held US biotech KSQ Therapeutics, a developer cancer therapies using its proprietary CRISPRomics discovery platform, has entered into a worldwide license agreement with Swiss pharma giant Roche. 14 July 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024